氟伐他汀对合并高胆固醇血症的慢性丙型肝炎的抗病毒疗效的影响

目的：观察氟伐他汀对合并高胆固醇血症的慢性丙型肝炎的抗病毒疗效的影响。方法选取2006年9月至2008年9月合并高胆固醇血症慢性丙型肝炎60例，观察组30例，对照组30例，所有患者均予聚乙二醇干扰素α-2a＋利巴韦林治疗；观察组患者加用氟伐地汀；用药后4、12、24、36、48周及停药后12周、24周复查病毒RNA定量。结果氟伐他汀治疗合并高LDL血症的慢性丙型肝炎的患者的早期病毒学应答（EVR）、治疗结束时病毒学应答（ETVR）和持续病毒学应答（SVR）均显著高于对照组（53.3%vs.46.7%，85.1%vs.63.3%，81.5%vs.53.3%，P＜0.05）。结论氟伐他汀有利于提高合并高胆固醇血症的慢性丙型肝炎患者的抗病毒疗效。

Effect of fluvastatin on the antiviral treatment on patients with chronic hepatitis C and hypercholesterolemia

Objective To investigate the efficacy of fluvastatin on antiviral treatment on the patients with chronic hepatitis C and hypercholesterolemia. Methods Sixty patients with chronic hepatitis C and hypercholesterolemia in September 2006 to September 2008 in Youan Hospital divided into observation group and control group, 30 cases each group. All patients were treated with peginterferon α-2a and ribavirin. The patients in investigation group were treated with fluvastatin additionally. The HCV RNA number were tested at 4, 12, 24, 48 weeks after treatment initiation and at 12 and 24 weeks after termination. Rusults Both early virological response and sustained virological response of investigation group were much higher than those of control group（53.3% vs 46.7%, 81.5%vs 53.3%, P〈0.05）. Conclusion Fluvastatin might be benefit to the patients with chronic hepatitis C and hypercholesterolemia.